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Abstract
Purpose: Transnasal administration is one of the most common routes for allergen challenge in
mouse models of airway diseases. Although this technique is widely used, neither the amount of
allergen that reaches the lung nor its airway distribution has been well established. We used
positron emission tomography (PET) and computed tomography (CT) to examine the anatomical
distribution of a solution containing a tracer immediately after transnasal delivery and to
determine the possible influence of age and administered volume.
Procedures: Forty-six female BALB/c mice were divided into three groups according to
instillation volume and age: (A) 15 μl, 8–10 weeks old (N=10), (B) 30 μl, 8–10 weeks old (N=
20), and (C) 30 μl, 32 weeks old (N=16). Anesthetized animals underwent a dynamic scan in a
dedicated small-animal PET scanner immediately after transnasal administration of a solution
containing 18FDG. Regions of interest were used to obtain quantitative data. Animals were also
imaged with a small-animal CT scanner to obtain complementary anatomical information.
Results: Mean±SD (5.69±4.51%) of the solution administered reached the lungs in group A,
41.84±8.03% in group B, and 36.65±16.15% in group C. A comparable percentage was
delivered to the left and right lungs in all the groups. Analysis of variance revealed a significant
difference between the groups in the proportion of the solution that reached the lungs depending
on the injection volume (PG0.001), but not depending on animal age.
Conclusions: In this first report on quantitative imaging by PET and CT in small animals, we
confirmed the suitability of the transnasal route with an instilled volume of 30 μl delivering fluids
into the lower airways, although only about 40% of the dose reaches the lungs.
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Introduction
Allergic bronchial asthma is a chronic inflammatorydisease with an increasing worldwide prevalence.
Current pharmacologic therapies provide nonspecific short-
term relief from symptoms, but the efficacy of etiological
treatments based on allergen immunotherapy is still limited.
Nowadays, many asthma studies focus on reducing morbid-
ity. However, ethical restrictions on human studies make
murine models particularly useful, since it has been
demonstrated that the allergic response in mouse lungs
closely resembles certain aspects of human asthma [3].
Experimental protocols for airway allergen challenge in
these models of airway disease involve three main routes of
administration: (1) transnasal [4], (2) intratracheal [7], and
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(3) inhaled [11, 12, 18]. Our study focuses on transnasal
administration. Although the procedure has been widely
used, neither the amount of allergen that reaches the lungs
nor the distribution within the airways has been well
established.
Positron emission tomography (PET) is a noninvasive
imaging technique that allows for reliable measurement of
the concentration of radiotracers in the body of a living
subject. Recent advances in detector design have enabled the
construction of high-resolution, small-animal PET scanners
for imaging small laboratory animals, thus opening new
areas of research on the brain, tumors, preclinical evaluation
of new radiopharmaceuticals, as well as gene expression and
gene therapy [15, 17].
Computed tomography (CT) is also a noninvasive
imaging technique that uses X-rays to provide anatomical
information. Image contrast depends on the attenuation
coefficient of the X-rays and is directly correlated to tissue
density [15]. CT has proven to be a useful complementary
tool when combined with other modalities of functional
imaging, since it provides structural information that makes
it possible to accurately locate activity distribution within the
body of a living animal.
We used PET and CT scanners to assess both the
anatomical distribution and the amount of solution which
reached the lungs immediately after transnasal delivery.
Materials and Methods
Animals and Experimental Protocol
Forty six female BALB/c mice were used in the experiment.
Animals were purchased from IFFA CREDO SA (Barcelona,
Spain), maintained at a constant temperature (24±0.5°C) under a
12 h light/dark cycle, and permitted free access to commercial
rodent laboratory chow and water. The following three groups were
established based on volume administered and age:
(a) Group A (N 10): 15 μl administered to 8 to 10 week old
mice;
(b) Group B (N 20): 30 μl administered to 8 to 10 week old
mice; and
(c) Group C (N 16): 30 μl administered to 32 week old mice.
Once mice were anesthetized with inhaled Forane® (Abbott
Laboratories Ltd., Kent, UK), they were placed upright and
received the positron emitting tracer 2 deoxy 2 [18F]fluoro D glu
cose (18FDG) transnasally. The tracer was dissolved in 15 μl (8.18±
1.77 MBq) or 30 μl (11.98±3.69 MBq) of saline. Animals were
administered half the volume through each nostril with a
micropipette and were kept upright for ~30 s to facilitate the
access of the tracer to the airway. One minute after the instillation,
the mice were anesthetized with isofluorane (5% for induction and
2% for maintenance in 100% O2) and were introduced in the PET
scanner in head in prone position. The mice were dynamically
scanned for 320 s, generating a study with eight frames of 40 s
each. Moreover, ten mice from group B were also scanned using a
static whole body imaging protocol of 320 s with two bed positions
and one frame to check that the solution did not enter compart
ments other than the lungs or upper airways.
All experimental animal procedures were performed in compli
ance with the European Communities Council Directive of 24
November 1986 (86/609/EEC) and were approved by the Institu
tional Animal Care and Use Committee of the Hospital.
PET Imaging
PET scans were performed with a small animal PET scanner (rPET
SUINSA Medical Systems, Madrid, Spain) [15], and acquisitions
were centered on the thoracic region. Tomographic images were
reconstructed using a 3D FBP (filtered back projection) algorithm
that produced 55 slices measuring 55×55 pixels each. In the case of
whole body imaging protocol, the study had 102 slices of 55×
55 pixels. The voxel size was 0.81×0.81×0.81 mm3, and the
spatial resolution in these images was 1.65 mm full width at half
maximum isotropic. The energy window was 400 700 keV, and
decay, deadtime, randoms, and scatter corrections were applied.
Attenuation correction was not performed since the attenuation
correction factor for mouse lungs should be close to 1 due to the
very low amount of tissue present on the thoracic tomographic
slices. Previous studies [19] have demonstrated that it is possible to
perform accurate quantification of 18FDG PET images of small
mice without attenuation correction even in more dense tissues as
the liver. Therefore, we assume that attenuation correction would
not significantly change the quantitative results.
Analysis of PET Data
To obtain quantitative data of lung activity, three regions of interest
(ROI) were drawn on coronal, sagittal, and transaxial sections of
the dynamic studies: right lung, left lung, and total field of view
(FOV) activity. Time activity curves were obtained and extrap
olations to time 0 were calculated by fitting the data to an
exponential function. These values at time 0 were used to estimate
the initial distribution, specifically the fraction of the activity going
to the lungs with respect to the injected dose (represented by the
total FOV activity). Results are thus presented as a percentage of
total FOV activity. Figure 1 shows an example of these time
activity curves in a mouse instilled with 30 μl.
CT Study
Those animals scanned using a PET whole body imaging protocol
were also scanned on a small animal CT scanner [16]. CT images
covered the animal from nose to abdomen and were reconstructed
using a modified Feldkamp, Davis, and Kress algorithm. The voxel
size was 0.25×0.25×0.25 mm3. Tube current and amperage
(50 kV, 200 μA) were optimized for lung imaging.
The tracheal volume in a subgroup of eight animals from group
B was obtained from the CT images by drawing on coronal sections
an ROI corresponding to the tracheal lumen.
CT and PET images were co registered using a marker based
rigid registration method to obtain an initial realignment, followed
by a refinement step based on an automatic mutual information
registration algorithm [2, 10].
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Statistical Analysis
ROI data were analyzed by means of one way analysis of variance
(ANOVA) followed by post hoc tests (Scheffé). Hypothesis of
normality of distributions and homogeneity of variance were
assessed using the Kolmogorov Smirnov and Levene tests,
respectively.
Results
An average of 5.69±4.51% (mean±SD) of the administered
solution reached the lungs in group A, 41.84±8.03% in
group B and 36.65±16.15% in group C. All the studies
included the animal head well inside the field of view. The
proportion of solution delivered to each lung in the different
groups is summarized in Table 1.
ANOVA revealed a significant difference between groups
in the total proportion of administered solution that reached
the lungs, depending on injection volume (PG0.001), but not
on animal age.
No significant differences in the distribution of the
solution were observed between the left and right lungs in
any of the groups.
The percentage of solution reaching the lungs showed very
low values (G4%) in four animals from group A. Figure 2
shows projection images from two mice immediately after
administering the tracer solution (FDG). The solution was
properly instilled in the case showed in panel a, but not in the
case showed in panel b.
The tracheal volume of mice 8–10 weeks old was 13.6±
1.8 μl.
The co-registered PET and CT studies of mice scanned
using a whole body imaging position protocol confirmed the
anatomical location of the tracer after transnasal administra-
tion. Activity was detected in lungs, trachea, and upper
airways (nose, throat), but not in the gastrointestinal tract
(Fig. 3). Figure 4 shows combined PET-CT axial sections of
a representative mouse after transnasal administration of
30 μl containing approximately 300 μCi.
Discussion
The study of in vivo animal models has provided valuable
information on several aspects of the pathogenesis and
treatment of allergy and asthma. Murine models of allergic
asthma have usually been generated by inducing systemic
sensitization followed by an airway challenge using nebu-
lized or transnasal allergen [4, 20]. In the present study, we
evaluated the amount of solution reaching the lung and its
distribution within the airways after a transnasal challenge
by 18FDG by PET and CT imaging.
Table 1. Percentage of solution delivered to each lung in the different groups of mice
Right Lung Left Lung Both Lungs
Group A (N 10) 15 μl, 8 10 weeks old 2.63±2.72 3.06±2.07 5.69±4.51
Group B (N 20) 30 μl, 8 10 week old 25.21±7.25* 16.62±3.66* 41.84±8.03*
Group C (N 16) 30 μl, 32 week old 17.91±7.87* 18.74±12.28* 36.65±16.15*
N represents the number of animals in each group. Values are expressed as mean percentage±SD
*PG0.001 versus group A
Fig. 1. Left panel, Left lung and right lung activity are measured by 3D segmentation of the lungs on the CT image. Right
panel, dynamic curves of tracer distribution in a mouse instilled with 30 μl of FDG, obtained at 40 s/frame (green line, total FOV
activity; blue line, right lung; and red line, left lung.
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Fig. 3. Co-registered PET and CT coronal slices at the first time frame. From top left to bottom right, the slices go from ventral
to dorsal. The larynx is clearly visible on the more ventral slices (upper panel).
Fig. 2. Projection images from two mice immediately after administering the tracer solution (FDG). a Coronal view of a properly
instilled animal (head is up, the two bright blobs in the middle are the lungs). b Coronal view of a bad instillation (head is up;
there is almost none activity at lung level).
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In this study, we used an aqueous solution of FDG to
examine the anatomical distribution of the dose after
intranasal administration. The activity of FDG decreased
with time, as shown in Fig. 1, probably due to the diffusion
of FDG into the bloodstream and posterior uptake by
different tissues. The acquisition duration of our study
(about 5 min) was too short to see clear FDG uptake in
any specific organ. The study of this diffusion and
redistribution process is not of interest in this work;
therefore, we used time=0 extrapolated values to estimate
the initial dose distribution.
In our work, we assume that immediately after the
administration of FDG, all the dose remains in the FOV,
which covers the upper respiratory tract, lungs, esophagus,
and stomach. In this regard, any other tracer could have been
used instead of FDG, as any specific metabolization of the
radiopharmaceutical is irrelevant at time=0 when the initial
distribution only depends on physical mechanisms.
The influence of the age of the mice on the tracer
distribution was also evaluated. Mice are born without
alveoli, and these are formed rapidly within the first few
postnatal weeks [1]. The development of the alveoli and the
elastic fiber is complete by 38 days of age [8]. The present
study was performed on animals with fully developed
alveoli. We studied animals that were 8 to 10 weeks old
(young adults) and 32 weeks old (old adults). Young adults
are usually used for acute asthma studies and old adults are
used in chronic asthmatic models. We did not detect any
age-related differences in tracer distribution in the lungs of
the animals that received 30 μl, indicating that transnasal
challenge may be valuable in both acute and chronic
models.
Efficiency of dose delivery to the lung can be defined as
the percentage of the dose deposited in the lungs (dl) relative
to the dose delivered (dd) [(Table 1; Efficiency=100×dl/
dd)]. After administering the allergen transnasally with the
animal supine and its neck hyperextended, Tomaki et al.
[13] reported that 31% of administered particles finished in
the lower airways. In this study, the efficiency of transnasal
administration was examined using Evans blue dye and
isolating tissue from the trachea, bronchi, lungs, esophagus,
stomach, and nose. Our study is the first to use an in vivo
molecular imaging technique (PET) to evaluate the efficien-
cy of transnasal challenge in mice, and we obtained an
overall value in the lungs close to 40% of the delivered dose.
The regional distribution of FDG in the lungs was
apparently homogenous, but no attempt was made to
perform a quantitative assessment.
The optimum volume instilled for challenge is a
controversial issue. In some protocols, the instilled volumes
ranged from 50 μl [5, 9, 12] to 100 μl over several days [6].
Other authors use only 10 μl over several days [14]. We
compared the effect of two different volumes of instillation,
15 and 30 μl, and found significant differences between
them: The animals that received 15 μl showed approximate-
ly 35% less activity in the lungs than those that received
30 μl. These results agree with the data shown by Tomaki et
al. [13] who reported that 31% of the dose went into the
Fig. 4. Images from a representative mouse after transnasal administration of 30 μl containing 11.1 MBq of FDG. Left panel,
Co-registered PET and CT studies superimposed. Right panel, Axial sections of the lungs in the PET study.
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lungs with 25 μl. In our case, when we administered 30 μl,
the amount of tracer in the lungs reached about 40%. We
obtained a tracheal volume of about 13.6±1.8 μl in mice
aged 8–10 weeks. This volume could explain the approxi-
mately sixfold difference in mean lung distribution between
animals from group A and groups B/C, as it implies that a
minimum volume of 30 μl may be necessary in order to
ensure that at least 40% of the administered dose actually
reaches the lungs. This result is interesting, since it is
necessary to find a compromise between the volume
administered (trying not to drown the animal) and the
amount of allergen/medication that reaches the lungs. We
had previously tried administering 50 μl, but some mice died
(data not shown). In fact, we have demonstrated that the
instillation of allergen in a volume of 30 μl can induce lung
inflammation in airway disease models at a lower risk of
drowning [4].
In those cases of group A where the dose reaching the
lungs was very low, most of the FDG solution appeared at
the upper nasal passages and esophagus. This probably
means that either the positioning for instillation, the
instillation duration, or the instilled volume was not
technically adequate. In this way, the large variation within
and between groups may reflect the technical difficulty of
the nasal administration, which sometimes even leads to a
totally incorrect dose delivery, particularly when the instilled
volume is small, as is the case with group A. According to
this interpretation, a proper instillation technique may
constitute a key point of the procedure, and a number of
failures in the administration have to be accepted as a
possibility by the experimenters.
Our study showed the advantage of using multimodality
image registration (PET and CT studies). PET allowed us to
quantify the distribution of the tracer administered trans-
nasally in the upper airways (nose, throat), trachea, and the
lungs (Fig. 3). CT images provide anatomical information
that, co-registered with PET, enabled us to demonstrate that
the solution reaches the anatomical target in a sufficient
amount.
One possible limitation of our study derives from the
extrapolation of time–activity curves to time=0 by fitting
data to an exponential function. We chose an exponential
function because of its good fit to our data and because it is a
simple and robust model. We did not test whether another
function could yield more precise results.
We believe that the information provided by these results
may be of interest for researchers working in the field of
airway allergen challenge, as there is no available data on
the amount of allergen that may really reach the lung in in
vivo studies. It may also be advisable for the researchers to
be aware about the possibility of an incorrect instillation that
may lead to a near-zero dose delivered to the lung in a small
percentage of the cases.
In conclusion, in this first report on quantitative imaging
by PET and CT in small animals, we confirmed that the
transnasal route with an instilled volume of 30 μl is suitable
for delivering fluids into the lower airways, although only
about 40% of the dose reaches the lungs.
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